Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit

Inclusion Criteria: * Korean men and women aged ≥30 years and ≤65 years at the time of informed consent. * At screening, subjects with a score of 3 (moderate) or higher on the Mid Face Volume Deficit Scale (MFVDS), as assessed by independent on-site evaluators, with symmetrical deficits in both mid-face regions including the zygomatic area, anterior medial cheek, and subzygomatic area. * Subjects who agree not to undergo any other procedures (e.g., filler injections other than the investigational medical device, laser treatment, chemical peeling, botulinum toxin, or facial plastic surgery) during the course of the clinical trial. * Subjects who are able to understand and follow instructions and participate throughout the entire duration of the clinical trial. * Subjects who voluntarily provide written informed consent to participate in the clinical trial. Exclusion Criteria: * History of anaphylaxis or severe allergic reactions requiring treatment. * History of hypertrophic scars, keloids, or post-inflammatory hyperpigmentation. * Use of anticoagulants (e.g., warfarin), antiplatelets, thrombolytics, immunosuppressants, or NSAIDs within 2 weeks prior to screening, or intake of other agents that may prolong coagulation time (e.g., vitamin E, garlic, ginkgo); Low-dose aspirin ≤300 mg/day permitted; participation allowed after ≥5 half-lives washout of the active compound. * Use of topical facial medications (steroids, retinoids; excluding cosmetics) within 4 weeks prior to scr…